Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025
MRVI Investors Have Opportunity to Lead Maravai Lifesciences Holdings, Inc. Securities Fraud Lawsuit
Express News | Maravai LifeSciences Q1 Revenue USD 56.6 Million Vs. IBES Estimate USD 44.1 Million
Maravai LifeSciences Holdings, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
RBC Capital Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Maintains Target Price $7
New Analyst Forecast: $MRVI Given $5.0 Price Target
